wellness


Irwin Naturals Expands Operations into Northeast with Acquisition of Vermont-Based Clinic

June 17th, 2022 - Ryan Allway

Company continues national growth trajectory for Emergence clinics focusing on total wellness including the therapeutic use of ketamine   LOS ANGELES, June 17, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today it has entered into a binding agreement to acquire the assets of Hobie Fuerstman D O […]

TripSitter.Clinic Launches New App for At-Home Ketamine Therapy

June 3rd, 2022 - Ryan Allway

TORONTO, June 3, 2022 /CNW/ – TripSitter Clinic Ltd. (CSE: KETA) (FSE: UY0) (“TripSitter” or the “Company”), today announced the official launch of the TripSitter App, a simple and free App that makes it easy for users to access TripSitter Clinics’ services.   TripSitter.Clinic Launches New App for At-Home Ketamine Therapy (CNW Group/TripSitter Clinic Ltd.) CEO of TripSitter […]

Jupiter Wellness Appoints E-Commerce & Marketing Team to Drive Sales of its Growing Portfolio of Proprietary Health and Wellness Brands

April 18th, 2022 - Ryan Allway

JUPITER, FL / ACCESSWIRE / April 18, 2022 /Jupiter Wellness, Inc. (NASDAQ:JUPW) today announced that it has appointed three sales and marketing executives to its team to drive sales of its science-backed proprietary brands and products.   Over the past two years, Jupiter has built a portfolio of award-winning wellness brands including CaniSun, fitCBD, Jack, Wellness CBD […]

Hemp for Health Consolidates Its Share Capital

November 29th, 2021 - Ryan Allway

Vancouver, British Columbia–(Newsfile Corp. – November 29, 2021) – Further to its news release of November 17, 2021, HEMP FOR HEALTH INC. (CSE: HFH) (FSE: 9HH) (the “Company”) announces that effective at the opening of trading on Thursday, December 2nd, 2021 (the “Effective Date”) the shares of the Company will commence trading on the Canadian Securities […]

Ehave Looks to Power the Psychedelics Revolution

June 30th, 2021 - Ryan Allway

Mental illness will cost the global economy $16 trillion by 2030 due to early-onset and lost productivity, with an estimated 12 billion working days lost due to these conditions each year.  Conventional therapies have a mixed track record, but psychedelics have shown much promise in recent years. The challenge for researchers and medical professionals is […]

Abba Medix Surpasses 900 Active Medical Patient Registrations, Representing 50% Growth Since January 2021

June 15th, 2021 - Ryan Allway

TORONTO, June 15, 2021 /CNW/ – Canada House Wellness Group (CSE: CHV) (“Canada House” or the “Company“), a fully integrated medical cannabis company, is pleased to announce that its wholly owned subsidiary, Abba Medix Corp. (“Abba“) has surpassed 900 active medical patient registrations.  Abba has experienced accelerated patient growth over the past 6 months with active medical patient […]

Psychedelics Wellness Company Delic: Proven Management Team with a Star-Studded Board

April 9th, 2021 - Ryan Allway

The psychedelics  sector is quickly evolving into a multi-billion-dollar industry with a growing number of publicly traded companies. As with any new industry, there are many companies backed by little more than financiers looking to make a quick dollar before moving on to the next opportunity, which makes it important for investors to know who’s […]

Ovation Science Takes Topical Cannabis to the Next Level with Its Patented Drug Delivery Technology

March 23rd, 2021 - Ryan Allway

Cannabinoids have become some of the most popular health and wellness products in the world. For example, CBD-infused topicals are expected to reach $4.5 billion in sales by 2025, according to Cultivating Wellness, which represents a 540% increase since 2020. At the same time, topicals infused with THC or combinations of CBD and THC are […]

There’s no Magic Answer to the Question, “Can I Patent Magic Mushrooms?”

February 24th, 2021 - Ryan Allway

“Patent pending” is a phrase you are likely familiar with. You have seen it stamped on the side of some doodad at the mall or heard it on the TV show that you are binge watching, and you think to yourself, “Wow, I wish I could invent something that everyone thinks is really cool”. Most […]

Psychedelic Clinical Trials & Who’s Behind Them

February 18th, 2021 - Ryan Allway

The psychedelics industry has experienced unprecedented growth over the past few years, driven by a combination of emerging research, regulatory support and investor interest. With a growing number of organizations in the space, it can be difficult for investors to keep track of what clinical trials are ongoing and what opportunities lie in the horizon. […]

Revive Therapeutics Aims to Bring Psychedelics to Market

February 17th, 2021 - Ryan Allway

The psychedelic drug market is projected to grow at a 16.3% compound annual growth rate to reach nearly $7 billion by 2027, according to Data Bridge Market Research. While there are a growing number of publicly traded companies in the space, the best opportunities have the right combination of experience, intellectual property and clinical trials. […]

Psychedelics: Significant Investor Interest Despite the Pandemic

February 16th, 2021 - Ryan Allway

  The COVID-19 pandemic may be ravaging large swaths of the economy, but the stock market has consistently hit new record highs. After spending several years under-the-radar, the psychedelics industry is experiencing a renaissance driven by a combination of FDA-driven catalysts and soaring investor interest in a new class of potential blockbuster therapeutics.  Let’s take […]

Royalty Streaming: A Different Way to Get Exposure to the Cannabis Market

February 9th, 2021 - Ash Stringer

  When cannabis legalization started to gain momentum in 2012 with Washington and Colorado legalizing recreational marijuana, everyone knew it was going to be a big industry. For nearly a decade now, the investment community has ridden the volatility of the emerging market that generated $13.8 billion in sales in North America in 2019. Analysts […]

CBD Innovator, HempFusion, Makes Successful Debut on TSX

January 13th, 2021 - Ryan Allway

  HempFusion Wellness Inc. (TSX: CBD-U) shares soared over 65% following their successful debut on the Toronto Stock Exchange (TSX) on Wednesday, January 6, 2021. Cannabidiol, or CBD, has become one of the most popular health and wellness products in the world over the past couple of years. According to Research and Markets, the global […]

HempFusion Gears Up for IPO on the TSX

December 7th, 2020 - Ryan Allway

HempFusion Wellness Inc., a leading health and wellness CBD company, recently closed the order book for its proposed initial public offering (IPO), marking another step closer to becoming a publicly-traded company on the Toronto Stock Exchange (TSX) over the coming months. Completion of this proposed initial public offering has the potential to accelerate the company’s […]

Why Focus on Cannabis & Mushroom Extracts?

November 25th, 2020 - Ryan Allway

  Cannabis extracts are poised to become a $28.5 billion market by 2027, according to Grand View Market Research, representing a 16.6% compound annual growth rate. At the same time, the functional mushroom market is forecast to reach $34.3 billion by 2024, which represents a respectable 8% compound annual growth rate. Let’s take a look […]

CBD Makes Its Way into Mainstream Retail

November 19th, 2020 - Ryan Allway

The U.S. market for CBD products is projected to reach $23.7 billion by 2023, according to Brightfield Group, representing a seven-fold increase in the market’s size. While it’s one of the fastest-growing subsets of the multi-trillion-dollar wellness industry, CBD products remain absent from most mass-market retailers. CVS became the first large-scale retailer to offer CBD […]

CB Therapeutics: Producing Rare Cannabinoid & Psychedelic Molecules at Scale

November 10th, 2020 - Ryan Allway

The cannabis industry has evolved from the legalization of dried cannabis to an increasingly detailed understanding of individual cannabinoids. While THC and CBD are the two most common, researchers are increasingly interested in CBC, THCV and other rare cannabinoids that could have specific and desirable effects on certain medical indications. The problem is that these […]

3 Psychedelische Business Modelle (und was am besten für Investoren ist)

October 23rd, 2020 - Ryan Allway

Die Psychedelikaindustrie hat das Interesse von Pharmaunternehmen geweckt, die nach sichereren und effektiveren Produkten suchen, um ungedeckte medizinische Bedürfnisse im Bereich der psychischen Gesundheit zu befriedigen. Während psychedelische Moleküle vielversprechend sind, verlangen die Pharmahersteller, dass die Moleküle durch wissenschaftliche Techniken verbessert werden, um bestimmte therapeutische Ziele zu erreichen und Toxizitäten zu reduzieren. Es gibt drei […]

3 Psychedelic Business Models (and What’s Best for Investors)

October 22nd, 2020 - Ryan Allway

The psychedelics industry has captured the interest of pharmaceutical companies seeking safer and more effective products to address unmet medical needs in mental health. While psychedelic molecules have shown promise, pharmaceutical manufacturers are likely to require that the molecules be improved through scientific engineering to meet specific therapeutic goals and reduce toxicities. There are three […]

Mydecine Innovations Group Announces The Official Mindleap Health Mobile App Launch in IOS and Android Stores Today

September 30th, 2020 - Ryan Allway

  DENVER, Colorado, USA – September 30th, 2020 – Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company”) is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), a digital telehealth mobile application for mental coaching and wellbeing, has officially launched and is available for download today: Download on Android Download on IOS […]

MindLeap Health Enters into Fast-Growing Telehealth Market

September 29th, 2020 - Ryan Allway

The COVID-19 pandemic has led to dramatic changes in healthcare. In addition to mobilizing a vaccine in record time, the pandemic could permanently alter the way that many people seek medical care, shifting from in-person to telehealth. These changes have created an enormous opportunity for companies to innovate in the remote delivery of health services. […]

Christina Lake Cannabis: Disrupting the Market with Ultra-Low Cost Production

September 17th, 2020 - Ryan Allway

Cannabis is quickly moving from a hot commodity to a regular commodity as a growing number of licensed producers put pressure on prices. While the government hopes that falling prices push out black market competition, many companies have seen their margins contract after just a short time in production—spelling danger for investors in the space. […]

3 Beverage Mega-Trends that Investors Should Watch

June 15th, 2020 - Ryan Allway

Beverages play a key role in almost everyone’s life—from coffee in the morning to an alcoholic drink at dinner or with friends. While the same large companies have dominated the space for years, smaller innovators have experienced the fastest growth rates as they launch high-growth products before getting snapped up by larger competitors. The key […]

Israel Gives Final Go-Ahead for Cannabis Exports: Here’s Who Could Profit

June 5th, 2020 - Ryan Allway

Israel gave final approval in mid-May for exports of medical cannabis, paving the way for more than one billion shekels ($273 million) in annual revenue. The country will become one of just three countries that have approved the export of medical cannabis to countries that permit its use—after Canada and the Netherlands— when the law […]

How to Invest in a Global Cannabis Portfolio

May 20th, 2020 - Ryan Allway

North America’s cannabis industry may capture the most headlines, but there are many cannabis frontier markets to keep in mind. In fact, North America represented just 25%, or $86 billion, of the $344 billion global cannabis market in 2018, according to New Frontier Data. Asia, Europe, Africa, Latin America, Oceana and the Caribbean are all […]

THC BioMed Reports Growing Revenue & Profitability

April 22nd, 2020 - Ryan Allway

Cannabis investors had already been shifting from “unproven potential” to “profitability” over the past several quarters prior to the global health crisis. With the COVID-19 outbreak, investors have fled previous investments to profitable companies that aren’t reliant on costly or dilutive funding to sustain their operations. THC BioMed Intl Ltd. (CSE: THC) recently recorded its […]

CFN Enterprises (OTCQB: CNFN) Names BlockChain Pioneer Tim Vasko to Board of Advisors

April 22nd, 2020 - Ryan Allway

“We are pleased to welcome Tim Vasko, the Founder and CEO of BlockCerts Blockchain, to the Board of Advisors of CFN Enterprises. Tim is a cloud and blockchain pioneer, creating companies that have processed billions of transactions, proprietary tracking applications and a patent providing secure virtual spaces,” said Brian Ross, Chairman and CEO of CFN Enterprises Inc.

Led By An Expert Team In The Beverage Industry- Innoviom Is Adapting and Driving Their Business Despite The Current Pandemic

April 16th, 2020 - Ryan Allway

  The COVID-19 outbreak has severely disrupted the economy and could push the world into the sharpest economic contraction since the Great Depression in the 1930s. While the cannabis industry has been largely spared thus far, companies have been forced to adopt new business models and strategies to succeed in the ‘new normal’. Innoviom, a […]

Ehave, Inc. Appoints Dr. Mark Braunstein as Chief Psychedelic Officer

April 6th, 2020 - Ryan Allway

Dr. Braunstein is recognized worldwide in Psychedelic Psychiatry, which entails treating psychiatric disorders with psychedelics Dr. Braunstein is a renowned expert on psychedelic therapy and addiction. As a pioneer in psychedelic medicine research, he specializes in the treatment of ADHD, depression, anxiety, bipolar disorder, substance abuse, oppositional defiance, personality disorders, and treatment resistance. He has […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading